|
Novel genomic alterations and transcriptomic-based tumor microenvironment classification of sarcoma and their impact on treatment decision making. |
|
|
|
Stock and Other Ownership Interests - BostonGene |
|
|
|
Stock and Other Ownership Interests - BostonGene |
|
|
|
Stock and Other Ownership Interests - BostonGene |
|
|
|
Stock and Other Ownership Interests - BostonGene |
Patents, Royalties, Other Intellectual Property - BostonGene |
|
|
|
|
|
|
Stock and Other Ownership Interests - BostonGene |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - BostonGene |
Patents, Royalties, Other Intellectual Property - BostonGene |
|
|
|
Stock and Other Ownership Interests - BostonGene |
Patents, Royalties, Other Intellectual Property - BostonGene |
|
|
|
|
|
|
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - BostonGene |
Patents, Royalties, Other Intellectual Property - BostonGene |
|
|
No Relationships to Disclose |
|
J Andrew Andrew Livingston |
Consulting or Advisory Role - Foghorn Therapeutics |
Research Funding - Repare Therapeutics (Inst) |
Other Relationship - Guidepoint Global |
|
|
Stock and Other Ownership Interests - AstraZeneca; Merck; Moderna Therapeutics; Pfizer; TRACON Pharma |
|
Consulting or Advisory Role - AADi; Daiichi Sankyo; Gerson Lehrman Group; Guidepoint Inc |
Research Funding - AADi (Inst); Athenex (Inst); Novartis (Inst); TRACON Pharma (Inst) |
Patents, Royalties, Other Intellectual Property - Author Royalties from Uptodate |
Travel, Accommodations, Expenses - Daiichi Sankyo |
|
|
Stock and Other Ownership Interests - AADi; Cellestia Biotech; Immix BioPharma |
Honoraria - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma; Tyme |
Consulting or Advisory Role - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma |
Speakers' Bureau - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma |
Research Funding - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma |
|
|
Consulting or Advisory Role - BioAtla; C4 Therapeutics; Daiichi Sankyo/UCB Japan; Eisai; Foghorn Therapeutics; Ikena Oncology |
Research Funding - Agios (Inst); Bavarian Nordic; Bayer (Inst); BioAtla (Inst); C4 Therapeutics (Inst); CBA Research (Inst); Eisai (Inst); Epizyme (Inst); Foghorn Therapeutics (Inst); Ikena Oncology (Inst); Jazz Pharmaceuticals (Inst); Kronos Bio (Inst); Macrogenics (Inst); Merck KGaA (Inst); PharmaMar (Inst); Rain Therapeutics (Inst); Repare Therapeutics (Inst); Servier (Inst); Springworks Therapeutics (Inst); Sumitomo Dainippon Pharma Oncology (Inst) |